Scholarlink

<p>Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory disease that significantly impairs quality of life. Dupilumab, a monoclonal antibody targeting IL-4 and IL-13 signaling, has emerged as a highly effective therapy for patients with severe, uncontrolled CRSwNP. This retrospective real-life cohort study assessed the impact of dupilumab on symptom severity using both subdomain and individual item scores of the validated Sino-Nasal Outcome Test-22 (SNOT-22). Eighty-nine patients with CRSwNP were evaluated before and after six months of dupilumab treatment. Significant and clinically meaningful improvements were observed in all four SNOT-22 domains—nasal, otologic/facial pain, sleep, and emotional—with the most pronounced reduction in nasal symptoms. Item-level analysis revealed the greatest improvements in decreased sense of smell/taste, nasal congestion, thick nasal discharge, post-nasal drip, and the need to blow the nose—symptoms also rated most severe at baseline. These findings underscore dupilumab’s effectiveness in alleviating the most burdensome aspects of CRSwNP. Domain- and item-level SNOT-22 assessment may offer a clearer view of disease burden and treatment impact than the total score alone.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of dupilumab on SNOT-22 domain and individual item scores in chronic rhinosinusitis with nasal polyps

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月30日

查看全文
  • Angelika Lang,
  • Michael Habenbacher,
  • Ulrich Moser,
  • Jakob Pock,
  • Thomas Lampl,
  • Clemens Holzmeister,
  • Ahmed Abaira,
  • Jakob Staudinger,
  • Alexandros Andrianakis

摘要

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory disease that significantly impairs quality of life. Dupilumab, a monoclonal antibody targeting IL-4 and IL-13 signaling, has emerged as a highly effective therapy for patients with severe, uncontrolled CRSwNP. This retrospective real-life cohort study assessed the impact of dupilumab on symptom severity using both subdomain and individual item scores of the validated Sino-Nasal Outcome Test-22 (SNOT-22). Eighty-nine patients with CRSwNP were evaluated before and after six months of dupilumab treatment. Significant and clinically meaningful improvements were observed in all four SNOT-22 domains—nasal, otologic/facial pain, sleep, and emotional—with the most pronounced reduction in nasal symptoms. Item-level analysis revealed the greatest improvements in decreased sense of smell/taste, nasal congestion, thick nasal discharge, post-nasal drip, and the need to blow the nose—symptoms also rated most severe at baseline. These findings underscore dupilumab’s effectiveness in alleviating the most burdensome aspects of CRSwNP. Domain- and item-level SNOT-22 assessment may offer a clearer view of disease burden and treatment impact than the total score alone.